Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
about
Sorafenib: from literature to clinical practiceManagement of hepatocellular carcinoma with portal vein thrombosisDrug therapy for advanced-stage liver cancerCancer and liver cirrhosis: implications on prognosis and managementSelection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.Methodological assessment of HCC literaturePotentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.Update on new approaches in the management of hepatocellular carcinoma.Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Refining sorafenib therapy: lessons from clinical practice.Managing complications in cirrhotic patientsPediatric hepatocellular carcinoma: challenges and solutions.Hepatocellular carcinoma: the place of new medical therapies.Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines.The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot studySorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisHepatocellular carcinoma in children: hepatic resection and liver transplantation
P2860
Q26826933-C79EF7F9-E719-4371-9FE3-F015F9370986Q26996578-5071CAF6-01A7-452C-A9D8-AC1C8550DE89Q27004410-107DA8C1-DDB8-4EBF-9153-4E85E5B10D39Q28068579-58AEACAE-15C7-4D91-8EDC-D283A7A8B6D2Q30486078-BF83A8B1-F274-4CB9-9BE3-5F8F6EE2C749Q34241371-5789B91F-7665-4FA6-B351-CCD1448A4F75Q34372111-75DAF126-9F3F-4C28-B44D-4DE000E3A69EQ35167764-1BFA1F5F-138F-4298-B2EE-8BDFED3BA03AQ35225534-EA89F17B-B0E3-475D-9F29-BC0DBA7F2C97Q36963820-2CFA2333-47EA-4017-8C83-F13BC3883768Q37017008-4C78D43B-0602-4D5F-986F-D544268B24B0Q37356150-20247F28-48FF-43DE-B65B-C27E544C30B3Q37952231-1BED89B9-E871-4C51-AB8A-687E2A2A4B9AQ38099680-D882C3C6-C47A-412D-B657-192BA4385FC4Q38264146-EC2CE820-A020-4CEC-9FDA-7B0EB2BF80E3Q38344890-7424A333-59C2-47F1-9837-56860E6AB864Q38987929-CD8FBF99-DACC-43F2-BB1F-70FC148DC8D1Q41174836-8CF728D4-2EDB-496B-933B-E88540A4E830Q47320493-697FB17C-47E2-4CBE-8531-386ACBA28AEFQ50559019-65B6816D-BFB2-4ADB-9AE1-E04B874BA8F6Q51168197-01E28CA5-6BFC-46A9-AD99-F76803FAD380Q54342105-9CFE442E-1557-4AE7-8502-A0D84F3205A1Q54559815-61106038-E45D-46A7-BCE9-BAC233E74CA4Q57168139-54B48C7B-F25E-467A-A5D9-BD924D67AF17Q57758019-078C21F7-0E03-48B9-B122-91AE15A1841EQ58555478-1DCBBACC-1207-47E7-AF8A-FD7C64C8E408
P2860
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@en
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@nl
type
label
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@en
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@nl
prefLabel
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@en
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
@nl
P2093
P1476
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
@en
P2093
Armando Santoro
Johannes Lammer
Luigi Bolondi
Olivier Rosmorduc
Tim F Greten
P304
P356
10.1097/MEG.0B013E328333DF23
P577
2010-04-01T00:00:00Z